MA56121A - Procédés d'identification d'attributs de protéines thérapeutiques - Google Patents

Procédés d'identification d'attributs de protéines thérapeutiques

Info

Publication number
MA56121A
MA56121A MA056121A MA56121A MA56121A MA 56121 A MA56121 A MA 56121A MA 056121 A MA056121 A MA 056121A MA 56121 A MA56121 A MA 56121A MA 56121 A MA56121 A MA 56121A
Authority
MA
Morocco
Prior art keywords
methods
therapeutic protein
identifying therapeutic
protein attributes
attributes
Prior art date
Application number
MA056121A
Other languages
English (en)
Inventor
Pavel Bondarenko
Jill A Crouse-Zeineddini
Scott Thomas Kuhns
Andrew Nichols
Rachel Liuqing Shi
Gang Xiao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA56121A publication Critical patent/MA56121A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • G01N33/547—Synthetic resin with antigen or antibody attached to the carrier via a bridging agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA056121A 2019-06-05 2020-06-05 Procédés d'identification d'attributs de protéines thérapeutiques MA56121A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857637P 2019-06-05 2019-06-05
US202062968682P 2020-01-31 2020-01-31

Publications (1)

Publication Number Publication Date
MA56121A true MA56121A (fr) 2022-04-13

Family

ID=71944196

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056121A MA56121A (fr) 2019-06-05 2020-06-05 Procédés d'identification d'attributs de protéines thérapeutiques

Country Status (9)

Country Link
US (1) US20220260584A1 (fr)
EP (2) EP3980786B1 (fr)
JP (1) JP7636352B2 (fr)
AU (1) AU2020288652A1 (fr)
CA (1) CA3138941A1 (fr)
ES (1) ES2997211T3 (fr)
MA (1) MA56121A (fr)
MX (1) MX2021014733A (fr)
WO (1) WO2020247790A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4065593A4 (fr) * 2019-11-26 2024-04-03 Merck Sharp & Dohme LLC Chromatographie d'interaction hydrophobe à ultra-performance en ligne pour surveiller au moins un attribut de produit
WO2022175728A1 (fr) * 2021-02-19 2022-08-25 Waters Technologies Corporation Procédés de cartographie peptidique de protéines du virus adéno-as associé (vaa)
AU2022262421A1 (en) 2021-04-23 2023-10-19 Amgen Inc. Anti-tslp antibody compositions and uses thereof
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
CA3226323A1 (fr) * 2021-07-13 2023-01-19 Regeneron Pharmaceuticals, Inc. Strategie fondee sur une spectrometrie de masse pour la determination de variants associes a un produit d'un produit biologique
JP2024530003A (ja) 2021-08-06 2024-08-14 アムジエン・インコーポレーテツド 治療用タンパク質の単離
WO2025076303A1 (fr) * 2023-10-05 2025-04-10 Amgen Inc. Dosage de protéomique peptidique associé au complexe majeur d'histocompatibilité (cmh) (mapp) pour l'évaluation du risque d'immunogénicité d'attributs biothérapeutiques
WO2025155798A2 (fr) * 2024-01-18 2025-07-24 Amgen Inc. Procédés d'analyse de protéines thérapeutiques co-formulées
US20260015427A1 (en) 2024-06-25 2026-01-15 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
ATE525462T1 (de) * 2004-07-02 2011-10-15 Eisai R&D Man Co Ltd Proteomanalyseverfahren für phosphoryliertes protein
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP5038407B2 (ja) * 2006-06-14 2012-10-03 ジョンズ ホプキンズ ユニバーシティー 疾患のバイオマーカーとしてのアルブミン結合性タンパク質／ペプチド複合体
CA2691157A1 (fr) 2007-06-20 2008-12-24 Irm Llc Procedes et compositions pour traiter des maladies allergiques
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8478537B2 (en) * 2008-09-10 2013-07-02 Agilent Technologies, Inc. Methods and systems for clustering biological assay data
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
ES2806146T3 (es) * 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L

Also Published As

Publication number Publication date
EP4517327A2 (fr) 2025-03-05
AU2020288652A1 (en) 2021-11-18
MX2021014733A (es) 2022-04-06
EP3980786A1 (fr) 2022-04-13
JP2022535042A (ja) 2022-08-04
WO2020247790A1 (fr) 2020-12-10
EP3980786B1 (fr) 2024-10-16
JP7636352B2 (ja) 2025-02-26
CA3138941A1 (fr) 2020-12-10
ES2997211T3 (en) 2025-02-14
US20220260584A1 (en) 2022-08-18
EP4517327A3 (fr) 2025-05-07

Similar Documents

Publication Publication Date Title
EP3899034C0 (fr) Procédés d'analyse d'arn
EP3891755A4 (fr) Système d'identification, d'extraction et de prédiction de concepts cliniques et procédés associés
EP3948492A4 (fr) Appareil de panneau d'affichage intelligent et procédés associés
EP3897402A4 (fr) Instruments chirurgicaux comprenant des mécanismes permettant d'identifier et/ou de désactiver des cartouches d'agrafeuse
EP3655006A4 (fr) Protéines de fusion insuline-fc à action ultra-longue et procédés d'utilisation
MA53094A (fr) Protéine de liaison à l'antigène anti-steap1
EP3824796A4 (fr) Système d'endoscope
EP3834159A4 (fr) Systèmes et procédés permettant d'identifier l'identité d'un produit
MA52963A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
EP3838108A4 (fr) Système d'endoscope
EP3491017A4 (fr) Procédés d'identification d'anticorps bloquant les récepteurs lilrb
EP3874455A4 (fr) Système intelligent et procédés d'identification de cible thérapeutique
EP3488018A4 (fr) Procédés et compositions pour l'identification de protéines
EP3487998A4 (fr) Compositions et procédés d'identification de cibles polypeptidiques de liaison à l'arn
EP3634992A4 (fr) Procédés et compositions pour l'identification d'épitopes
EP3958727A4 (fr) Procédés d'analyse spatiale de protéines et kits associés
EP4081939A4 (fr) Procédé d'identification de l'authenticité d'un d'objet
EP3980067A4 (fr) Protéine de fusion anticorps-interleukine et procédés d'utilisation
EP3856905A4 (fr) Procédés et compositions permettant d'augmenter l'expression de protéines et/ou de traiter un trouble d'haplo-insuffisance
MA52196A (fr) Moyen d'identification de véhicule
EP3859332A4 (fr) Procédé de dosage d'hémoglobine glyquée (%)
EP3779458A4 (fr) Système d'analyse automatisé
EP3859338A4 (fr) Réactif de dosage de l'hémoglobine, kit de dosage et procédé de dosage
DE602004018249D1 (de) Verfahren zur Dearomatisierung von Molkeprotein
EP3881325A4 (fr) Procédés d'identification de variants génétiques